CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

C Masini, A Berselli + Show 15 more

Open Access

https://doi.org/10.1093/annonc/mdx423

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 18, 2017
License type: elsevier-specific: oa user license

Affiliation: ASM International, Istituto Ramazzini, Institut Gustave Roussy, Ospedale Antonio Cardarelli, Istituto Oncologico Veneto, Mylan (Switzerland), Ospedale di Parma, Azienda Ospedaliero-Universitaria Cagliari, Istituti Ospitalieri di Cremona, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", A. O. Ordine Mauriziano di Torino, Universidad de Magallanes, Hospital Oncológico Andrés Grillasca, Azienda Ospedaliera Universitaria Integrata Verona

#First-line Metastatic Renal Cell Carcinoma #Efficacy Of Pazopanib + Show 3 more

Abstract
Full-Text PDF
Similar Papers

Abstract

CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

Full Text

Published version (

Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title

Journal

Date

Author

View more papers

Translate this paper in your preferred language
Listen to the abstract of this paper

Save
Share
Export